Abstract
Abstract Background and Aims Plasma Leucine-Rich alph-2-Glycoprotein 1(LRG1) is an new biomarker for inflammatory and angiogenetic diseases. whether levels of plasma LRG1 correlate with the co-morbidities of End stage renal disease (ESRD) patients is unknown. Method Plasma LRG-1 and high-sensitivity C-reactive protein were analyzed by ELISA in samples from 169 hemodialysis patients from the Immunity in ESRD study (iESRD study). Baseline co-morbidities were recorded through chart review of medical history. Results High level of LRG 1 showed high mortality in the ESRD. In multivariate-adjusted logistic regression models, higher LRG1 was significantly associated with 5 year mortality after adjusting for gender, hemoglobin, diabetes, hypertension, and level of C-reactive protein. Conclusion LRG1 is a possible poor prognosis marker in ESRD. Higher LRG-1 showed high prevalent CAD and PAOD in our study before. The role of LRG1 and the associated cardiovascular diseases should be analyzed the mechanism in this patient population.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
